WilmerHale Reps Editas Medicine in $94.4 Million IPO

Download IconDownload Print IconPrint

WilmerHale Reps Editas Medicine in $94.4 Million IPO

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016. The IPO was the first in the US in 2016.

The WilmerHale team on the transaction was led by Partners Steven D. Singer and Rosemary G. Reilly and included Counsel Jeffries Oliver-Li, and Associates Britt Eichner and Brett Bromann (corporate); as well as Partner Kim Wethly and Counsel Ciara Baker (tax). 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel